Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


High-Definition Erenna® Technology; Powered by Singulex

Product Description

Erenna_w_screen_clear.gif
Singulex, Inc., is a leader in advanced biomarker research, deploying high precision, high sensitivity, digital immunoassay technology to enable groundbreaking discovery, innovate therapies and improved healthcare.

The Erenna® Immunoassay System, powered by Singulex's patented single-molecule detection technology, accurately, precisely and reliably quantifies low-abundance biomarkers at or below sub-picogram concentrations – even in healthy individuals. This unique high-definition technology enhances the clinical utility of biomarkers and allows researchers to gain insights into drug safety and efficacy.

  • Quantifying the Previously Undetectable
  • Uncovering Novel Biology
  • Accelerating Discovery
  • Generating Relevant Data
  • Requiring Fewer Data Points for Critical Decision Making
  • Reducing Program Costs & Improving ROI

The Erenna Immunoassay System includes fully equipped instrumentation, integrated and prepared reagents for high-precision, ultrasensitive immunoassays, and dedicated Sgx link™ software to automatically analyze data and display detailed assay reports. 

The Singulex Solution is flexible to meet your needs and includes the Erenna Immunoassay System, High-Definition Immunoassays and a full range of Custom Services;  Sample Testing, Assay Development and  Antibody Derivatization Services; to accelerate your clinical trials & therapeutics management, and translational life science research.

Unless otherwise noted, Singulex products are for research use only and not intended for diagnostics use.

Contact for More Information.

Product High-Definition Erenna® Technology; Powered by Singulex
Company Singulex - Product Directory
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Singulex - Product Directory
1701 Harbor Bay Parkway, Alameda, California 94502, USA

Tel: +1.888.995.6955
Fax: +1.510.995.9090
Email: info@singulex.com



Scientific News
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!